Abstract
Prion diseases are rare, rapidly progressive, fatal neurodegenerative illnesses caused by an abnormal isoform of the native prion protein. Creutzfeldt-Jakob disease (CJD) is the most prevalent human prion disease with three possible etiologies: sporadic, genetic, and acquired. Although acquired forms of prion disease have received the most attention, most cases are sporadic or genetic and are thus unpreventable. There is some literature on neurotransmitter system dysregulation in animal and human models of prion diseases. Several studies indicate that there is a disproportional amount of serotonin dysregulation in prion diseases and that prion-mediated cytotoxicity may be blocked by N-methyl Daspartate (NMDA) receptor antagonists. Prion disease therapeutic investigations have mainly consisted of basic science research, which has elucidated the importance of molecular structure in preventing prion protein conversion. Typical neuroleptics and tricyclic antidepressants have been the primary psychotropic medications studied in humans due to their heterocyclic structures. Recent studies have correlated lipid disruption to these structurally similar compounds with antiprion activity. Preliminary studies suggest that lithium mediated inhibition of glycogen synthetase kinase 3 and lithium-induced autophagy may be avenues for further research. Many studies require replication in other experimental settings. Thus far, treatment strategies have focused on aborting prion protein conversion and as such have limited therapeutic usefulness given the rapidity of disease progression and difficulty in establishing ante-mortem diagnoses of prion diseases. There is a paucity of research examining the prevention of prion diseases in at risk populations (i.e. genetic and acquired prion diseases).
Keywords: Prion disease, prion, Creutzfeldt-Jakob disease, neurotransmitters, treatment, pharmacology, antipsychotics, antidepressants
CNS & Neurological Disorders - Drug Targets
Title: Psychotropic Medications and the Treatment of Human Prion Diseases
Volume: 8 Issue: 5
Author(s): Brian S. Appleby
Affiliation:
Keywords: Prion disease, prion, Creutzfeldt-Jakob disease, neurotransmitters, treatment, pharmacology, antipsychotics, antidepressants
Abstract: Prion diseases are rare, rapidly progressive, fatal neurodegenerative illnesses caused by an abnormal isoform of the native prion protein. Creutzfeldt-Jakob disease (CJD) is the most prevalent human prion disease with three possible etiologies: sporadic, genetic, and acquired. Although acquired forms of prion disease have received the most attention, most cases are sporadic or genetic and are thus unpreventable. There is some literature on neurotransmitter system dysregulation in animal and human models of prion diseases. Several studies indicate that there is a disproportional amount of serotonin dysregulation in prion diseases and that prion-mediated cytotoxicity may be blocked by N-methyl Daspartate (NMDA) receptor antagonists. Prion disease therapeutic investigations have mainly consisted of basic science research, which has elucidated the importance of molecular structure in preventing prion protein conversion. Typical neuroleptics and tricyclic antidepressants have been the primary psychotropic medications studied in humans due to their heterocyclic structures. Recent studies have correlated lipid disruption to these structurally similar compounds with antiprion activity. Preliminary studies suggest that lithium mediated inhibition of glycogen synthetase kinase 3 and lithium-induced autophagy may be avenues for further research. Many studies require replication in other experimental settings. Thus far, treatment strategies have focused on aborting prion protein conversion and as such have limited therapeutic usefulness given the rapidity of disease progression and difficulty in establishing ante-mortem diagnoses of prion diseases. There is a paucity of research examining the prevention of prion diseases in at risk populations (i.e. genetic and acquired prion diseases).
Export Options
About this article
Cite this article as:
Appleby S. Brian, Psychotropic Medications and the Treatment of Human Prion Diseases, CNS & Neurological Disorders - Drug Targets 2009; 8 (5) . https://dx.doi.org/10.2174/187152709789541961
DOI https://dx.doi.org/10.2174/187152709789541961 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Heart and Brain Axis Targets in CNS Neurological Disorders
Recently there has been a surge of interest in delving deeper into the complex interplay between the heart and brain. This fascination stems from a growing recognition of the profound influence each organ holds over the other, particularly in the realm of central nervous system (CNS) neurological disorders. The purpose ...read more
Lifestyle Interventions to Prevent and Treat Cognitive Impairment and Dementia
More than 55 million people live with dementia worldwide. By 2050, the population affected by dementia will exceed 139 million individuals. Mild cognitive impairment (MCI) is a pre-dementia stage, also known as prodromal dementia, affecting older adults. MCI emerges years before the manifestation of dementia but can be avoidable and ...read more
Novel Treatments in Subarachnoid Hemorrhage
The current landscape of therapeutic strategies for subarachnoid hemorrhage (SAH), a significant adverse neurological event commonly resulting from the rupture of intracranial aneurysms, is rapidly evolving. Through an in-depth exploration of the natural history of SAH, historical treatment approaches, and emerging management modalities, the present work aims to provide a ...read more
Pathogenic Proteins in Neurodegenerative Diseases: From Mechanisms to Treatment Modalities
The primary objective of this thematic issue is to elucidate the molecular mechanisms by which pathogenic proteins contribute to neurodegenerative diseases and to highlight current and emerging therapeutic strategies aimed at mitigating their effects. By bringing together cutting-edge research and reviews, this issue aims to: 1.Enhance Understanding: Provide a comprehensive ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Progress in Pharmacological Research of Antioxidants in Pathological Conditions: Cardiovascular Health
Recent Patents on Anti-Infective Drug Discovery An Overview of the Pharmacological Properties and Potential Applications of Natural Monoterpenes
Mini-Reviews in Medicinal Chemistry Effect of Depression on Self-Management Behaviors and Health Outcomes in Adults with Type 2 Diabetes
Current Diabetes Reviews A Mechanistic Review on Therapeutic Potential of Medicinal Plants and their Pharmacologically Active Molecules for Targeting Metabolic Syndrome
Current Pharmaceutical Design Physiological Effect and Therapeutic Application of Alpha Lipoic Acid
Current Medicinal Chemistry Exploring Nanotechnologies for the Effective Therapy of Malaria Using Plant-Based Medicines
Current Pharmaceutical Design Current Immunotherapies for Renal Cell Carcinoma
Current Molecular Pharmacology Adaptive and Compensatory Mechanisms of the Cardiovascular System and Disease Risk Factors in Young Males and Females
New Emirates Medical Journal Humic Acids as Therapeutic Compounds in Lead Intoxication
Current Clinical Pharmacology Beta Blockers can Mask not only Hypoglycemia but also Hypotension
Current Pharmaceutical Design Epidemiological Features of the 2019 Novel Coronavirus Outbreak in China
Current Topics in Medicinal Chemistry Clinical Impact of Co-medication of Levetiracetam and Clobazam with Proton Pump Inhibitors: A Drug Interaction Study
Current Drug Metabolism Pyrazolo-Triazolo-Pyrimidine Derivatives as Adenosine Receptor Antagonists: A Possible Template for Adenosine Receptor Subtypes?
Current Pharmaceutical Design Preeclampsia Prediction in Type 1 Diabetes and Diurnal Blood Pressure Methodology
Current Hypertension Reviews The Perils, Pitfalls and Opportunities of Using High Sensitivity Cardiac Troponin
Current Medicinal Chemistry Kinins and Cardiovascular Diseases
Current Pharmaceutical Design Computational Studies of Competitive Inhibitors of Nitric Oxide Synthase (NOS) Enzymes: Towards the Development of Powerful and Isoform-Selective Inhibitors
Current Medicinal Chemistry A New Direction in Ophthalmic Development: Nanoparticle Drug Delivery Systems
Current Pharmaceutical Design Interleukin 2 in Cancer Therapy
Current Medicinal Chemistry Usefulness of Home Blood Pressure in the Diagnosis and Control of Hypertension in Primary Care
Current Hypertension Reviews